Geode Capital Management LLC Boosts Stock Position in Arrowhead Pharmaceuticals, Inc. $ARWR

Geode Capital Management LLC lifted its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 4.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,264,963 shares of the biotechnology company’s stock after purchasing an additional 133,921 shares during the period. Geode Capital Management LLC’s holdings in Arrowhead Pharmaceuticals were worth $216,799,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Tsfg LLC purchased a new stake in shares of Arrowhead Pharmaceuticals during the fourth quarter worth about $25,000. iSAM Funds UK Ltd purchased a new stake in shares of Arrowhead Pharmaceuticals during the third quarter worth about $29,000. First Horizon Corp bought a new position in Arrowhead Pharmaceuticals in the fourth quarter worth about $32,000. WPG Advisers LLC raised its stake in Arrowhead Pharmaceuticals by 384.8% in the fourth quarter. WPG Advisers LLC now owns 543 shares of the biotechnology company’s stock worth $36,000 after buying an additional 431 shares in the last quarter. Finally, Hantz Financial Services Inc. raised its stake in Arrowhead Pharmaceuticals by 177.1% in the fourth quarter. Hantz Financial Services Inc. now owns 737 shares of the biotechnology company’s stock worth $49,000 after buying an additional 471 shares in the last quarter. 62.61% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, Director Hongbo Lu sold 2,970 shares of the firm’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $76.88, for a total transaction of $228,333.60. Following the completion of the transaction, the director owned 52,012 shares of the company’s stock, valued at approximately $3,998,682.56. This trade represents a 5.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Daniel Joseph Apel sold 13,095 shares of the firm’s stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $71.35, for a total transaction of $934,328.25. Following the transaction, the chief financial officer directly owned 162,905 shares of the company’s stock, valued at $11,623,271.75. This represents a 7.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 36,065 shares of company stock valued at $2,554,562. Corporate insiders own 3.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on ARWR. Royal Bank Of Canada increased their price target on shares of Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the stock an “outperform” rating in a research note on Friday, May 8th. Weiss Ratings downgraded shares of Arrowhead Pharmaceuticals from a “hold (c-)” rating to a “sell (d-)” rating in a research note on Wednesday, May 20th. Morgan Stanley raised shares of Arrowhead Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $78.00 to $100.00 in a research note on Tuesday, April 21st. Wall Street Zen downgraded shares of Arrowhead Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, HC Wainwright reissued a “buy” rating and issued a $100.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, March 25th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Arrowhead Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $87.80.

Arrowhead Pharmaceuticals Price Performance

ARWR stock opened at $70.82 on Wednesday. Arrowhead Pharmaceuticals, Inc. has a 1 year low of $14.30 and a 1 year high of $82.26. The company has a market cap of $9.98 billion, a P/E ratio of -32.94 and a beta of 1.28. The firm has a 50-day moving average of $69.93 and a 200 day moving average of $64.81. The company has a debt-to-equity ratio of 1.41, a current ratio of 6.23 and a quick ratio of 6.23.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its earnings results on Thursday, May 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.17. Arrowhead Pharmaceuticals had a negative net margin of 48.38% and a negative return on equity of 55.09%. The business had revenue of $73.74 million during the quarter, compared to the consensus estimate of $73.84 million. During the same quarter last year, the firm earned $2.75 earnings per share. The business’s revenue for the quarter was down 86.4% on a year-over-year basis. On average, sell-side analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -2.98 EPS for the current year.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.